Foundayo cut sleep apnea events by 44% without PAP. Can Lilly turn an obesity pill into its next OSA franchise?
Foundayo cut sleep apnea events by up to 44% in Phase 3 ATTAIN-OSA, giving Eli Lilly another potential obesity-linked OSA treatment.
Pharma & Biotech